PE20091586A1 - Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato - Google Patents

Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato

Info

Publication number
PE20091586A1
PE20091586A1 PE2009000511A PE2009000511A PE20091586A1 PE 20091586 A1 PE20091586 A1 PE 20091586A1 PE 2009000511 A PE2009000511 A PE 2009000511A PE 2009000511 A PE2009000511 A PE 2009000511A PE 20091586 A1 PE20091586 A1 PE 20091586A1
Authority
PE
Peru
Prior art keywords
amino
carboxamide
chloro
methylpyridine
phenoxy
Prior art date
Application number
PE2009000511A
Other languages
English (en)
Inventor
Michael Logers
Reinhold Gehring
Oliver Kuhn
Mike Matthaus
Klaus-Helmut Mohrs
Matthias Muller-Gliemann
Jurgen Stiehl
Mathias Berwe
Jana Lenz
Werner Heilmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091586(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091586A1 publication Critical patent/PE20091586A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]FENOXI}-N-METILPIRIDINA-2-CARBOXAMIDA Y SU SAL TOSILATO QUE COMPRENDE: A) REACCIONAR 4-CLORO-N-METILPIRIDIN-2-CARBOXAMIDA CON 4-AMINOFENOL RESULTANDO 4-(4-AMINOFENOXI)-N-METILPIRIDINA-2-CARBOXAMIDA; B) REACCIONAR COMPUESTO RESULTANTE CON ISOCIANATO DE 4-CLORO-3-TRIFLUOROMETILFENILO RESULTANDO EL COMPUESTO 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]FENOXI}-N-METILPIRIDINA-2-CARBOXAMIDA D) REACCIONAR COMPUESTO CON ACIDO p-TOLUENOSULFONICO. DICHO COMPUESTO ES INHIBIDOR DE ENZIMA Raf QUINASA SIENDO UTIL EN EL TRATAMIENTO DE TRANSTORNOS ANGIOGENICOS COMO EL CANCER
PE2009000511A 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato PE20091586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04023131 2004-09-29

Publications (1)

Publication Number Publication Date
PE20091586A1 true PE20091586A1 (es) 2009-10-31

Family

ID=35457568

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2009000511A PE20091586A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2005001144A PE20060825A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000510A PE20091585A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000509A PE20091584A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000512A PE20091587A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-cloro-n-metilpiridin-2-carboxamida

Family Applications After (4)

Application Number Title Priority Date Filing Date
PE2005001144A PE20060825A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000510A PE20091585A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000509A PE20091584A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
PE2009000512A PE20091587A1 (es) 2004-09-29 2005-09-28 Procedimiento para preparar 4-cloro-n-metilpiridin-2-carboxamida

Country Status (35)

Country Link
US (1) US8124782B2 (es)
EP (1) EP1797037B1 (es)
JP (2) JP2008514657A (es)
KR (1) KR101263032B1 (es)
CN (1) CN101052619B (es)
AR (1) AR053973A1 (es)
AU (1) AU2005289099B2 (es)
BR (1) BRPI0515944B1 (es)
CA (1) CA2581835C (es)
CU (1) CU23754B7 (es)
CY (1) CY1116126T1 (es)
DK (1) DK1797037T3 (es)
DO (1) DOP2005000183A (es)
EC (1) ECSP077357A (es)
ES (1) ES2532377T3 (es)
GT (1) GT200500269A (es)
HK (1) HK1113484A1 (es)
HN (1) HN2005000768A (es)
HR (1) HRP20150295T1 (es)
IL (1) IL182046A0 (es)
MA (1) MA28883B1 (es)
MY (1) MY149873A (es)
NO (1) NO339647B1 (es)
NZ (1) NZ554119A (es)
PE (5) PE20091586A1 (es)
PL (1) PL1797037T3 (es)
PT (1) PT1797037E (es)
SG (1) SG155997A1 (es)
SI (1) SI1797037T1 (es)
SV (1) SV2006002243A (es)
TW (1) TWI382973B (es)
UA (1) UA90691C2 (es)
UY (1) UY29143A1 (es)
WO (1) WO2006034796A1 (es)
ZA (1) ZA200702511B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
NZ553804A (en) * 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Thermodynamically stable form of bay 43-9006 tosylate
CN101052619B (zh) 2004-09-29 2012-02-22 拜耳先灵制药股份公司 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法
EP1868579B1 (en) 2005-03-07 2010-09-29 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2669158A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US8445687B2 (en) 2007-09-10 2013-05-21 Cipla Limited Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process
WO2009054004A2 (en) * 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
US8217061B2 (en) 2008-01-17 2012-07-10 Sicor Inc. Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
EP2142507A1 (en) * 2008-03-06 2010-01-13 Sicor, Inc. Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
US8604208B2 (en) 2009-09-24 2013-12-10 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2011058522A1 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
AU2011210326B2 (en) 2010-01-29 2014-10-09 Sun Pharmaceutical Industries Limited Sorafenib dimethyl sulphoxide solvate
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
EP2595628A1 (en) 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
CN103664771B (zh) * 2012-09-19 2016-03-30 齐鲁制药有限公司 索拉非尼的晶型a及其制备方法
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
CN104710354A (zh) * 2013-12-13 2015-06-17 江苏豪森药业股份有限公司 高纯度索拉非尼的制备方法
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) * 2014-12-01 2016-03-30 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) * 2017-10-26 2018-04-17 魏海霞 索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) * 2020-06-10 2021-12-10 杭州中美华东制药有限公司 索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) * 1988-05-27 1990-01-05 Konica Corp 非線形光学材料
JP2971291B2 (ja) * 1993-06-02 1999-11-02 田辺製薬株式会社 光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) * 1996-03-27 2007-01-10 ポーラ化成工業株式会社 新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) * 1996-03-28 1997-12-09 Ajinomoto Co Inc 新規キサントン誘導体
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
KR101091101B1 (ko) * 1999-01-13 2011-12-09 바이엘 헬스케어 엘엘씨 ｒａｆ 키나아제 저해제로서의 ω-카르복시아릴 치환 디페닐 우레아
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
WO2003047579A1 (en) * 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
KR20050087776A (ko) * 2002-08-13 2005-08-31 산도즈 아게 세프디니르 중간체
JP3763414B2 (ja) * 2002-10-21 2006-04-05 麒麟麦酒株式会社 Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
CN101052619B (zh) 2004-09-29 2012-02-22 拜耳先灵制药股份公司 制备4-{4-[({[4-氯-3-(三氟甲基)苯基]氨基}羰基)氨基]苯氧基}-n-甲基吡啶-2-甲酰胺的方法

Also Published As

Publication number Publication date
TW200626551A (en) 2006-08-01
CN101052619A (zh) 2007-10-10
MY149873A (en) 2013-10-31
SI1797037T1 (sl) 2015-06-30
NO339647B1 (no) 2017-01-16
SG155997A1 (en) 2009-10-29
ECSP077357A (es) 2007-04-26
AU2005289099A1 (en) 2006-04-06
HK1113484A1 (en) 2008-10-03
JP2013067625A (ja) 2013-04-18
PE20091587A1 (es) 2009-11-05
IL182046A0 (en) 2007-07-24
UY29143A1 (es) 2006-04-28
CA2581835C (en) 2012-12-18
DK1797037T3 (en) 2015-03-30
BRPI0515944A (pt) 2008-08-12
KR101263032B1 (ko) 2013-05-09
NZ554119A (en) 2010-07-30
NO20072173L (no) 2007-06-14
WO2006034796A1 (en) 2006-04-06
KR20070058676A (ko) 2007-06-08
US20080262236A1 (en) 2008-10-23
UA90691C2 (en) 2010-05-25
MA28883B1 (fr) 2007-09-03
PE20060825A1 (es) 2006-10-20
HN2005000768A (es) 2010-09-17
TWI382973B (zh) 2013-01-21
DOP2005000183A (es) 2006-03-31
CY1116126T1 (el) 2017-02-08
AU2005289099B2 (en) 2012-07-19
ES2532377T3 (es) 2015-03-26
PE20091585A1 (es) 2009-10-31
AR053973A1 (es) 2007-05-30
EP1797037B1 (en) 2014-12-17
CU20070069A7 (es) 2010-11-27
SV2006002243A (es) 2006-10-13
CA2581835A1 (en) 2006-04-06
CN101052619B (zh) 2012-02-22
CU23754B7 (es) 2012-01-31
GT200500269A (es) 2006-05-11
US8124782B2 (en) 2012-02-28
JP5583190B2 (ja) 2014-09-03
BRPI0515944B1 (pt) 2021-11-09
PL1797037T3 (pl) 2015-07-31
HRP20150295T1 (hr) 2015-05-22
JP2008514657A (ja) 2008-05-08
PE20091584A1 (es) 2009-10-28
EP1797037A1 (en) 2007-06-20
PT1797037E (pt) 2015-03-17
ZA200702511B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
PE20091586A1 (es) Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida y su sal tosilato
ECSP077356A (es) Forma termodinámicamente estable de una sal tosilato
Daigneault et al. Economic approach to assess the forest carbon implications of biomass energy
Atkinson et al. The Atlantic century: benchmarking EU & US innovation and competitiveness
UA111569C2 (uk) Комбінація діючих речовин, яка містить піридилетилбензаміди й інші діючі речовини
MY177066A (en) Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpridine-2-carboxamide, its salts and monohydrate
PE97899A1 (es) Forma de cristal � de la sal de adicion de acido metanosulfonico de n-[5-(4-(4-metilpiperazina metilbenzoilamido]-2-metilfenil]-4-(3-piridil)-2-pirimidina-amina
WO2009054004A3 (en) Process for the preparation of sorafenib
CL2011002958A1 (es) Composición que comprende ácido 4-oxo-4-[(2-feniletil)amino]-butírico y tolclofos-metilo; y método para controlar enfermedades en plantas.
RS54265B1 (en) ADHESIVE CAPSULITIS TREATMENT PROCEDURES
NO20052753L (no) Kombinasjonsprodukter med karboksylsyrederivater som inhiberer bindingen av integriner til deres reseptorer, og andre terapeutiske forbindelser.
EA200601334A1 (ru) Процесс кучного биовыщелачивания
Lemon et al. Measuring the Effects of Corporate Social Responsibility
Hellström et al. Combining case study and simulation methods in supply chain management research
Donkers The Embodied Co-Creative Process of Drawing
Bilberg et al. Smart Factory: Growth through Collaboration and Technology
DOP2005000184A (es) Forma termodinamicamente estable de una sal tosilato
Segoli et al. COCOREDP–An efficient co-creative model for competence development, by research, development, and practice engagement
Sanchez How can we introduce Nature-connection sensory experiences through architectural interior space in order to improve our health and wellbeing?
Schmeltz et al. The Power of a Creative Theme: A Large-scale Study of the Implications of Working with a “Forced” Creative Theme in Strategic Partnerships.
Erede Governing Corporations with Concentrated Ownership Structure: Can Hedge Funds Activism Play Any Role in Italy?
Lim et al. A comparison of the luminous environment in a modern house and a traditional house in Korea
Ulhøi et al. The firm-nature interaction: Past experiences and future challenge. Invited Speciel Expert Paper
Tuominen et al. The economic effects of energy conservation in the Finnish building stock
Heryanto A post-colonial subversive

Legal Events

Date Code Title Description
FC Refusal